As non-face-to-face sales became common in the aftermath of COVID-19 last year, Japanese pharmaceutical companies’ entertainment and sales promotional expenses decreased significantly.
The entertainment expenses of the eight Japanese pharmaceutical companies all dropped compared to 2019, reducing the total size by about a quarter from 3.9 billion won to 2.9 billion won.
Eisai Korea’s entertainment expenses in 2019 decreased by more than 300 million won from 1.5 billion won in 2019 to 1.2 billion won last year, and Astellas Pharma Korea reduced the entertainment expenses by nearly half from 500 million won.
Moreover, Otsuka Korea’s entertainment expenses have also been reduced by more than 100 million won from 300 million won to 200 million won, while that of Takeda Korea, Kyowa Kirin Korea, Mitsubishi Tanabe Pharma also fell by more than 50 million won. Santen Korea and Daiichi Sankyo Korea’s entertainment expenses also declined from 2019.
Sales promotional expenses have also been significantly reduced. According to the audit reports of five Japanese pharmaceutical companies, the combined sales promotional expenses were about 11.1 billion won, down about 2.2 billion won or 16.4% from 2019.
In particular, Astellas Pharma Korea cut by 1.1 billion won from 3.1 billion won to 2 billion won, and Santen Korea and Takeda Korea reduced their sales promotional expenses by 900 million won from 3.9 billion won to 3 billion won, and 2.9 billion won to 1.9 billion won.
Kyowa Kirin Korea also cut its sales promotional expenses from 600 million won mark in 2019 to 200 million won mark last year, but Daiichi Sankyo Korea’s sales promotional expenses increased by 1.2 billion won from 2.8 billion won to 4 billion won.
